Your browser doesn't support javascript.
loading
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.
Dhédin, Nathalie; Huynh, Anne; Maury, Sébastien; Tabrizi, Reza; Beldjord, Kheira; Asnafi, Vahid; Thomas, Xavier; Chevallier, Patrice; Nguyen, Stéphanie; Coiteux, Valérie; Bourhis, Jean-Henri; Hichri, Yosr; Escoffre-Barbe, Martine; Reman, Oumedaly; Graux, Carlos; Chalandon, Yves; Blaise, Didier; Schanz, Urs; Lhéritier, Véronique; Cahn, Jean-Yves; Dombret, Hervé; Ifrah, Norbert.
Afiliação
  • Dhédin N; Department of Hematology and University Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, University Hospital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France;
  • Huynh A; Department of Hematology, University Institute of Cancer, Toulouse, France;
  • Maury S; Department of Hematology, University Hospital Henri Mondor, AP-HP, Créteil, France;
  • Tabrizi R; Department of Hematology, University Hospital, Bordeaux, France;
  • Beldjord K; Department of Hematology and University Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, University Hospital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France;
  • Asnafi V; Department of Hematology, University Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades, INSERM U1151, and Onco-Hematology Laboratory, Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France;
  • Thomas X; Department of Hematology, Hospital Lyon Sud, Pierre Bénite, France;
  • Chevallier P; Department of Hematology, University Hospital, Nantes, France;
  • Nguyen S; Department of Hematology, University Hospital Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France;
  • Coiteux V; Department of Hematology, University Hospital, Lille, France;
  • Bourhis JH; Department of Hematology, Institut Gustave Roussy, Villejuif, France;
  • Hichri Y; Department of Hematology, University Hospital, Montpellier, France;
  • Escoffre-Barbe M; Department of Hematology, University Hospital, Rennes, France;
  • Reman O; Department of Hematology, University Hospital, Caen, France;
  • Graux C; Department of Hematology, University Hospital, Yvoir, Belgium;
  • Chalandon Y; Division of Hematology, Department of Medical Specialties, University Hospital, Geneva, and Faculty of Medicine, University of Geneva Switzerland and Swiss Group for Clinical Cancer Research, Bern, Switzerland;
  • Blaise D; Department of Hematology, Institut Paoli Calmettes, Marseille, France;
  • Schanz U; Division of Hematology, University Hospital of Zurich, Zurich, Switzerland;
  • Lhéritier V; Group for Research on Adult Acute Lymphoblastic Leukemia, Coordination Office, Pierre Bénite, France;
  • Cahn JY; Department of Hematology, University Hospital, Grenoble, France; and.
  • Dombret H; Department of Hematology and University Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, University Hospital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France;
  • Ifrah N; Department of Hematology and INSERM U 892/CNRS 6299, University Hospital, Angers, France.
Blood ; 125(16): 2486-96; quiz 2586, 2015 Apr 16.
Article em En | MEDLINE | ID: mdl-25587040
ABSTRACT
Because a pediatric-inspired Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) protocol yielded a markedly improved outcome in adults with Philadelphia chromosome-negative ALL, we aimed to reassess the role of allogeneic stem cell transplantation (SCT) in patients treated in the GRAALL-2003 and GRAALL-2005 trials. In all, 522 patients age 15 to 55 years old and presenting with at least 1 conventional high-risk factor were candidates for SCT in first complete remission. Among these, 282 (54%) received a transplant in first complete remission. At 3 years, posttransplant cumulative incidences of relapse, nonrelapse mortality, and relapse-free survival (RFS) were estimated at 19.5%, 15.5%, and 64.7%, respectively. Time-dependent analysis did not reveal a significant difference in RFS between SCT and no-SCT cohorts. However, SCT was associated with longer RFS in patients with postinduction minimal residual disease (MRD) ≥10(-3) (hazard ratio, 0.40) but not in good MRD responders. In B-cell precursor ALL, SCT also benefitted patients with focal IKZF1 gene deletion (hazard ratio, 0.42). This article shows that poor early MRD response, in contrast to conventional ALL risk factors, is an excellent tool to identify patients who may benefit from allogeneic SCT in the context of intensified adult ALL therapy. Trial GRAALL-2003 was registered at www.clinicaltrials.gov as #NCT00222027; GRAALL-2005 was registered as #NCT00327678.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto / Avaliação de Resultados em Cuidados de Saúde / Transplante de Células-Tronco / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto / Avaliação de Resultados em Cuidados de Saúde / Transplante de Células-Tronco / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2015 Tipo de documento: Article